Ildiko Csiki MD PhD
Cancer Genetics/Cancer Risk Assessment, Complementary and Integrative, Clinical Informatics
Chief Health AI Officer and Founder, Wondrlink
Join to View Full Profile
3400 Civic Center Blvd.Rad Onc/Trc 2 WestPhiladelphia, PA 19104
Phone+1 215-662-2428
Dr. Csiki is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ildiko Csiki, based in Orange County, CA specializes in oncology with subspecialties in cancer genetics/cancer risk assessment, complementary and integrative medicine, and clinical informatics. She completed her medical education and postgraduate training at Vanderbilt University. Currently, she serves as the Chief Health AI Officer at Wondrlink and is a Physician Co-Founder at Cancer Connector. Her previous roles include being the Chief Commercial and R&D Officer at City of Hope Comprehensive Cancer Center and an Assistant Professor at multiple institutions affiliated with the University of Pennsylvania. Dr. Csiki's research contributions include several publications on cancer treatment and therapies, with notable works published in journals such as Nature Medicine and Clinical Cancer Research. She is involved in clinical trials focused on advanced oncology therapies and has received CMS Meaningful Use Stage 1 Certification from Epic Systems Corporation.
Education & Training
Vanderbilt University Medical CenterResidency, Radiation Oncology, 2008 - 2012- Vanderbilt University Medical CenterInternship, Internal Medicine, 2007 - 2008
Vanderbilt University School of MedicineClass of 2007
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN Start of enrollment: 2019 Nov 11
- SNS-301 Monotherapy in High Risk MDS and CMML Start of enrollment: 2020 Apr 01
Publications & Presentations
PubMed
- 162 citationsPersonalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan
Nature Medicine. 2024-04-01 - 107 citationsImmunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow, Kimberly A. Kraynyak, Albert Sylvester
Clinical Cancer Research. 2019-01-01 - 18 citationsAnti-Vascular Endothelial Growth Factor Treatment in Combination with Chemotherapy Delays Hematopoietic Recovery Due to Decreased Proliferation of Bone Marrow Hematopo...Sergey V. Novitskiy, Ildiko Csiki, Yuhui Huang, David H. Johnson, Eva Harth
Journal of Thoracic Oncology. 2010-09-01
Press Mentions
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of Its Scientific Advisory BoardJuly 21st, 2021
Development of a Multi-Antigenic SARS-CoV-2 Vaccine Candidate Using a Synthetic Poxvirus PlatformNovember 30th, 2020- Chutes & Ladders—Novavax Appoints AstraZeneca Vet Dubovsky to CMO RoleJune 19th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
